Regeneron Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
Regeneron Pharmaceuticals has a total shareholder equity of $27.0B and total debt of $2.0B, which brings its debt-to-equity ratio to 7.3%. Its total assets and total liabilities are $34.4B and $7.4B respectively. Regeneron Pharmaceuticals's EBIT is $4.0B making its interest coverage ratio -8.1. It has cash and short-term investments of $10.5B.
Key information
7.3%
Debt to equity ratio
US$1.98b
Debt
Interest coverage ratio | -8.1x |
Cash | US$10.52b |
Equity | US$26.99b |
Total liabilities | US$7.38b |
Total assets | US$34.37b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: RGO's short term assets ($18.9B) exceed its short term liabilities ($3.6B).
Long Term Liabilities: RGO's short term assets ($18.9B) exceed its long term liabilities ($3.8B).
Debt to Equity History and Analysis
Debt Level: RGO has more cash than its total debt.
Reducing Debt: RGO's debt to equity ratio has increased from 0% to 7.3% over the past 5 years.
Debt Coverage: RGO's debt is well covered by operating cash flow (238.9%).
Interest Coverage: RGO earns more interest than it pays, so coverage of interest payments is not a concern.